Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR Mutation Positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Chemoradiation Therapy (PLATINUM Trial)

NCT05338619 is registered in ClinicalTrials.gov with Sung Yong Lee as lead sponsor.

NCT NCT05338619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05338619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR Mutation Positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Chemoradiation Therapy (PLATINUM Trial)
Lead sponsor
Sung Yong Lee
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2022
Completion date
March 2, 2026
Enrollment
77 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

egfr positive non-small cell lung cancer, non-small cell lung cancer stage iii, non-squamous non-small-cell lung cancer